Growth Metrics

Eli Lilly (LLY) Other Non-Current Assets (2016 - 2026)

Eli Lilly filings provide 18 years of Other Non-Current Assets readings, the most recent being $7.2 billion for Q1 2026.

  • On a quarterly basis, Other Non-Current Assets rose 19.03% to $7.2 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $7.2 billion, a 19.03% increase, with the full-year FY2025 number at $7.0 billion, up 22.24% from a year prior.
  • Other Non-Current Assets hit $7.2 billion in Q1 2026 for Eli Lilly, up from $7.0 billion in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $7.2 billion in Q1 2026 to a low of $4.3 billion in Q1 2022.
  • Median Other Non-Current Assets over the past 5 years was $4.9 billion (2023), compared with a mean of $5.3 billion.
  • Biggest five-year swings in Other Non-Current Assets: rose 4.27% in 2024 and later increased 29.03% in 2025.
  • Eli Lilly's Other Non-Current Assets stood at $4.3 billion in 2022, then rose by 15.05% to $5.0 billion in 2023, then grew by 14.63% to $5.7 billion in 2024, then rose by 22.24% to $7.0 billion in 2025, then grew by 3.42% to $7.2 billion in 2026.
  • The last three reported values for Other Non-Current Assets were $7.2 billion (Q1 2026), $7.0 billion (Q4 2025), and $6.4 billion (Q3 2025) per Business Quant data.